Advertisement
U.S. markets open in 5 hours 7 minutes

Praxis Precision Medicines, Inc. (PRAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
59.20-2.98 (-4.79%)
At close: 04:00PM EDT
56.25 -2.95 (-4.98%)
After hours: 07:42PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close62.18
Open62.18
Bid59.24 x 100
Ask59.98 x 100
Day's Range58.11 - 62.41
52 Week Range11.85 - 67.21
Volume262,816
Avg. Volume183,483
Market Cap783.707M
Beta (5Y Monthly)2.86
PE Ratio (TTM)N/A
EPS (TTM)-18.69
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est138.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PRAX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Praxis Precision Medicines, Inc
    Daily – Vickers Top Insider Picks for 03/01/2024The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    27 days agoArgus Research
View more
  • GlobeNewswire

    Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

    BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,318,585 shares of its common stock at a public offering price per share of $56.50 and, in lieu of shares of common stock, pre-funde

  • GlobeNewswire

    Praxis Precision Medicines, Inc. Announces Proposed Public Offering

    BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. All securities in the offering

  • Zacks

    Praxis (PRAX) Surges on Positive Epilepsy Study Results

    Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.